BioCentury | Jan 8, 2021
Deals

ArsenalBio reaches next stage of maturity with BMS deal

...Westlake Village BioPartners, PICI, Kleiner Perkins, the University of California San Francisco Foundation Investment Co., Euclidean Capital...
BioCentury | Oct 9, 2020
Emerging Company Profile

A2: targeting lost genetic material to distinguish tumors from normal cells

...50Funds raised: $136 millionInvestors: The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital...
BioCentury | Aug 5, 2020
Emerging Company Profile

Nura reveals neuroprotective lead target, first part of its neurology one-two punch

...founded Nura Bio Inc. in 2018, led the round with participation from Samsara BioCapital and Euclidean Capital...
...of employees: About 25 Funds raised: $75 million Investors: The Column Group, Samsara BioCapital and Euclidean Capital...
BioCentury | Jun 24, 2020
Finance

June 23 Quick Takes: Illumina selects first biotechs for U.K. accelerator; plus updates from the NASDAQ IPO queue, and venture rounds for Surrozen, Tara

...Group, Hartford Healthcare Trust and Horizons Ventures participated in the round, as did new investor Euclidean Capital...
BioCentury | May 2, 2020
Finance

Frazier backs $50M series B for Dascena’s disease prediction algorithms

...kidney injury. Frazier Healthcare Partners led the round with participation from Longitude Capital, existing investor Euclidean Capital...
BioCentury | Mar 25, 2020
Finance

‘Diversified’ gut-brain axis company Kallyope heading to clinic with $112M series C

...Inc.’s series B investors backed the new round: The Column Group, Lux Capital, Polaris Partners, Euclidean Capital...
BioCentury | Nov 21, 2019
Financial News

Nov. 20 Financial Quick Takes: Diagnostics play Lucence raises series A; plus Novo-Broad, PMV, Phoenix, Winterlight and BMS-Celgene

...investors Nextech Invest, Viking Global Investors and Boxer Capital of Tavistock Group. Existing investors Topspin, Euclidean Capital...
BioCentury | Oct 17, 2019
Emerging Company Profile

Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

...company’s investors include PICI, Kleiner Perkins, the University of California San Francisco Foundation Investment Co., Euclidean Capital...
...Parker Institute for Cancer Immunotherapy, Kleiner Perkins, University of California San Francisco Foundation Investment Company, Euclidean Capital...
BioCentury | Jan 11, 2019
Financial News

Ribon raises $65M series B to target monoPARPs

...The Column Group, Deerfield Management, U.S. Venture Partners, Osage University Partners, Takeda Ventures and Euclidean Capital...
BioCentury | Jan 4, 2019
Financial News

Ribon raises $65 million series B to target monoPARPs

...The Column Group, Deerfield Management, U.S. Venture Partners, Osage University Partners, Takeda Ventures and Euclidean Capital...
Items per page:
1 - 10 of 22
BioCentury | Jan 8, 2021
Deals

ArsenalBio reaches next stage of maturity with BMS deal

...Westlake Village BioPartners, PICI, Kleiner Perkins, the University of California San Francisco Foundation Investment Co., Euclidean Capital...
BioCentury | Oct 9, 2020
Emerging Company Profile

A2: targeting lost genetic material to distinguish tumors from normal cells

...50Funds raised: $136 millionInvestors: The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital...
BioCentury | Aug 5, 2020
Emerging Company Profile

Nura reveals neuroprotective lead target, first part of its neurology one-two punch

...founded Nura Bio Inc. in 2018, led the round with participation from Samsara BioCapital and Euclidean Capital...
...of employees: About 25 Funds raised: $75 million Investors: The Column Group, Samsara BioCapital and Euclidean Capital...
BioCentury | Jun 24, 2020
Finance

June 23 Quick Takes: Illumina selects first biotechs for U.K. accelerator; plus updates from the NASDAQ IPO queue, and venture rounds for Surrozen, Tara

...Group, Hartford Healthcare Trust and Horizons Ventures participated in the round, as did new investor Euclidean Capital...
BioCentury | May 2, 2020
Finance

Frazier backs $50M series B for Dascena’s disease prediction algorithms

...kidney injury. Frazier Healthcare Partners led the round with participation from Longitude Capital, existing investor Euclidean Capital...
BioCentury | Mar 25, 2020
Finance

‘Diversified’ gut-brain axis company Kallyope heading to clinic with $112M series C

...Inc.’s series B investors backed the new round: The Column Group, Lux Capital, Polaris Partners, Euclidean Capital...
BioCentury | Nov 21, 2019
Financial News

Nov. 20 Financial Quick Takes: Diagnostics play Lucence raises series A; plus Novo-Broad, PMV, Phoenix, Winterlight and BMS-Celgene

...investors Nextech Invest, Viking Global Investors and Boxer Capital of Tavistock Group. Existing investors Topspin, Euclidean Capital...
BioCentury | Oct 17, 2019
Emerging Company Profile

Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

...company’s investors include PICI, Kleiner Perkins, the University of California San Francisco Foundation Investment Co., Euclidean Capital...
...Parker Institute for Cancer Immunotherapy, Kleiner Perkins, University of California San Francisco Foundation Investment Company, Euclidean Capital...
BioCentury | Jan 11, 2019
Financial News

Ribon raises $65M series B to target monoPARPs

...The Column Group, Deerfield Management, U.S. Venture Partners, Osage University Partners, Takeda Ventures and Euclidean Capital...
BioCentury | Jan 4, 2019
Financial News

Ribon raises $65 million series B to target monoPARPs

...The Column Group, Deerfield Management, U.S. Venture Partners, Osage University Partners, Takeda Ventures and Euclidean Capital...
Items per page:
1 - 10 of 22